Evaluating principal surrogate markers in vaccine trials in the presence of multiphase sampling
DOI10.1111/BIOM.12737zbMath1415.62104OpenAlexW2724998238WikidataQ38707640 ScholiaQ38707640MaRDI QIDQ3119801
Publication date: 13 March 2019
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: http://europepmc.org/articles/pmc5743779
predictingestimated likelihoodprincipal surrogatecloseout placebo vaccinationbaseline predictormultiphase samplingpredictor subsamplingpseudoscore
Inference from stochastic processes and prediction (62M20) Applications of statistics to biology and medical sciences; meta analysis (62P10) Sampling theory, sample surveys (62D05)
Related Items (1)
Cites Work
- Validation of Surrogate end Points in Multiple Randomized Clinical Trials with Failure Time end Points
- The evaluation of surrogate endpoints.
- Predicting overall vaccine efficacy in a new setting by re-calibrating baseline covariate and intermediate response endpoint effect modifiers of type-specific vaccine efficacy
- Design and Estimation for Evaluating Principal Surrogate Markers in Vaccine Trials
- Comparing Biomarkers as Principal Surrogate Endpoints
- Statistical Identifiability and the Surrogate Endpoint Problem, with Application to Vaccine Trials
- Principal Stratification in Causal Inference
- Evaluating Candidate Principal Surrogate Endpoints
- Related Causal Frameworks for Surrogate Outcomes
- Estimation of Regression Coefficients When Some Regressors Are Not Always Observed
- A Pseudoscore Estimator for Regression Problems With Two-Phase Sampling
- Augmented Designs to Assess Immune Response in Vaccine Trials
- A Generalization of Sampling Without Replacement From a Finite Universe
This page was built for publication: Evaluating principal surrogate markers in vaccine trials in the presence of multiphase sampling
